Current Report Filing (8-k)
25 Maio 2023 - 6:19PM
Edgar (US Regulatory)
0001509745
false
0001509745
2023-05-25
2023-05-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 25, 2023
Leap Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-37990 |
|
27-4412575 |
(State or other jurisdiction of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
47 Thorndike Street, Suite B1-1
Cambridge, MA |
02141 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone
number, including area code: (617) 714-0360
N/A
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form
8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)). |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name
of each exchange on which registered |
Common Stock, par value $0.001 |
LPTX |
Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On May 25, 2023, Leap Therapeutics,
Inc. (the “Company”) issued a press release entitled “Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish
Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting.”
The full text of the press release is filed as Exhibit
99.1 to this Current Report on Form 8-K and incorporated herein by reference; provided, however that information on or connected to our
website referenced in the Company’s press release is expressly not incorporated by reference into or intended to be filed as a part
of this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
LEAP THERAPEUTICS, INC. |
|
|
Dated: May 25, 2023 |
By: |
/s/ Douglas E. Onsi |
|
Name: |
Douglas E. Onsi |
|
Title: |
Chief Executive Officer and President |
Leap Therapeutics (NASDAQ:LPTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Leap Therapeutics (NASDAQ:LPTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024